207 related articles for article (PubMed ID: 28867118)
41. Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear cause.
Rauscher I; Beer AJ; Schaeffeler C; Souvatzoglou M; Crönlein M; Kirchhoff C; Sandmann G; Fürst S; Kilger R; Herz M; Ziegler S; Schwaiger M; Eiber M
J Nucl Med; 2015 Mar; 56(3):430-5. PubMed ID: 25678485
[TBL] [Abstract][Full Text] [Related]
42. ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors.
Segtnan EA; Hess S; Grupe P; Høilund-Carlsen PF
PET Clin; 2015 Jan; 10(1):59-73. PubMed ID: 25455880
[TBL] [Abstract][Full Text] [Related]
43. Update on advances in molecular PET in urological oncology.
Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
[TBL] [Abstract][Full Text] [Related]
44. MR-based attenuation correction for cardiac FDG PET on a hybrid PET/MRI scanner: comparison with standard CT attenuation correction.
Vontobel J; Liga R; Possner M; Clerc OF; Mikulicic F; Veit-Haibach P; Ter Voert EE; Fuchs TA; Stehli J; Pazhenkottil AP; Benz DC; Gräni C; Gaemperli O; Herzog B; Buechel RR; Kaufmann PA
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1574-80. PubMed ID: 26091704
[TBL] [Abstract][Full Text] [Related]
45. Interventional positron emission tomography/computed tomography: state-of-the-art.
Shyn PB
Tech Vasc Interv Radiol; 2013 Sep; 16(3):182-90. PubMed ID: 23993081
[TBL] [Abstract][Full Text] [Related]
46. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
47. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
48. PET/MRI in Pediatric Neuroimaging: Primer for Clinical Practice.
Pedersen C; Aboian M; McConathy JE; Daldrup-Link H; Franceschi AM
AJNR Am J Neuroradiol; 2022 Jul; 43(7):938-943. PubMed ID: 35512826
[TBL] [Abstract][Full Text] [Related]
49. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
50. Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings.
Houshmand S; Salavati A; Segtnan EA; Grupe P; Høilund-Carlsen PF; Alavi A
PET Clin; 2016 Jan; 11(1):65-84. PubMed ID: 26590445
[TBL] [Abstract][Full Text] [Related]
51. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
52. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
53. Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies.
Pattison DA; Hofman MS
PET Clin; 2015 Oct; 10(4):461-76. PubMed ID: 26384593
[TBL] [Abstract][Full Text] [Related]
54. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
55. Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma.
Wang LJ; Wu HB; Wang M; Han YJ; Li HS; Zhou WL; Wang QS
Eur J Radiol; 2015 Nov; 84(11):2275-9. PubMed ID: 26388466
[TBL] [Abstract][Full Text] [Related]
56. PET/MR imaging: current and future applications for cardiovascular disease.
Naeger DM; Behr SC
Magn Reson Imaging Clin N Am; 2015 Feb; 23(1):95-103. PubMed ID: 25476678
[TBL] [Abstract][Full Text] [Related]
57. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
58. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.
Wright CL; Maly JJ; Zhang J; Knopp MV
PET Clin; 2017 Jan; 12(1):63-82. PubMed ID: 27863567
[TBL] [Abstract][Full Text] [Related]
59. (18)F FDG PET/CT versus CT/MR Imaging and the Prognostic Value of Contralateral Neck Metastases in Patients with Head and Neck Squamous Cell Carcinoma.
Park JT; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2016 May; 279(2):481-91. PubMed ID: 26653682
[TBL] [Abstract][Full Text] [Related]
60. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
